Alnylam Pharmaceuticals Inc to Discuss FDA Approval of AMVUTTRA (Vutrisiran) Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals Conference Call to discuss the FDA approval of AMVUTTRA. (Operator Instructions). Please be advised that this call is being taped at the company's request. I would now like to turn the call over to the company.
Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Akshay Vaishnaw, President; Pushkal Garg, Chief Medical Officer; and Tolga Tanguler, Chief Commercial Officer. Also joining us and available for Q&A are Jeff Poulton, Chief Financial Officer; and Rena Denoncourt, Vice President, TTR Franchise Lead; with John Vest, Vice President, Clinical Research.
For those of you joining us via conference call, the slides have been made available via webcast, can also be accessed by going to the Investor page of our website
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
